{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000070","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.601174+00:00","generated_at":"2026-06-15T08:39:40.193676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiora Pharmaceuticals reports Q1 net loss of $1.9M; positive clinical data for KIO-301, KIO-201, KIO-101","bullets":["Net loss narrowed to $1.9M from $3.6M in Q1 2022; cash & equivalents $3.4M plus $1.7M R&D tax receivables.","KIO-301 (ABACUS trial) showed profound light perception improvements in a blind RP patient; full results by end 2023.","KIO-201 Phase 2 PCED trial met primary endpoint in 5 of 8 patients at 4 weeks; planning registration study.","KIO-101 Phase 2 OPRA trial first patient enrolled in April; targeting ocular surface disease from autoimmune conditions.","Approximately $9.6M available under equity line of credit; R&D expenses fell to $0.4M from $0.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000070","json":"https://secwatch.observer/filing/0001372514-23-000070.json","markdown":"https://secwatch.observer/filing/0001372514-23-000070.md","text":"https://secwatch.observer/filing/0001372514-23-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/0001372514-23-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/kprx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:39:40.193676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68e226e8d7205ef54abf03b5a07f856f9799d220","claim":"KIORA PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: net income $1.9 million.","evidence_excerpt":"Net loss was $1.9 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/0001372514-23-000070-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$1.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}